GlassScriptPhysician profile
Jonathan J Whitfield
NPI 1871622654
$10,377.77
in general payments reported to CMS, 2019-2025
26 companies · $3,361 in 2025
The $3,361 reported for 2025 was more than what 96% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.33 · 2021: $667 · 2022: $1,179 · 2023: $2,072 · 2024: $3,029 · 2025: $3,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,462.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,559.57 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,595.61 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $830.21 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $825.02 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $809.96 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $769.73 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $540.81 | 2019-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $353.93 | 2022-2025 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $324.99 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $265.69 | 2023-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $199.09 | 2024-2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $180.08 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $166.65 | 2025 | Auvelity |
| Bausch Health US, LLC | $159.38 | 2021-2024 | Wellbutrin, Aplenzin |
| Collegium Pharmaceutical, INC. | $151.28 | 2025 | Jornay Pm |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $131.79 | 2021-2023 | Ingrezza |
| Corium, LLC | $130.17 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $112.15 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tris Pharma INC | $72.61 | 2024-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $40.45 | 2023 | Quviviq |
| Neos Therapeutics, LP | $39.63 | 2025 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $31.24 | 2024 | Loreev Xr |
| Noven Pharmaceuticals, INC. | $28.04 | 2024 | Xelstrym |
| Adlon Therapeutics L.P. | $24.01 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.05 | 2021 | |
| Allergan, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Whitfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.